Jove
Visualize
Contact Us

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

205
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
205
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

31
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
31
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

23
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
23
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

135
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
135
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

50
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
50
Two-Compartment Open Model: Extravascular Administration01:12

Two-Compartment Open Model: Extravascular Administration

124
The two-compartment model for extravascular administration represents a drug's absorption and distribution process. It features a central compartment, where the drug is first absorbed, and a peripheral compartment, which illustrates the drug's distribution throughout the body. The rate of change in drug concentration in the central compartment is calculated by three exponents: absorption, distribution, and elimination.
The absorption exponent (ka) indicates the speed at which the drug...
124
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  2. Development And Validation Of A Population Pharmacokinetic Model To Guide Perioperative Tacrolimus Dosing After Lung Transplantation.
  1. Home
  2. Development And Validation Of A Population Pharmacokinetic Model To Guide Perioperative Tacrolimus Dosing After Lung Transplantation.

Related Experiment Video

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.8K

Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung

Todd A Miano1,2, Athena F Zuppa3, Rui Feng1

  • 1Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

JHLT Open
|March 27, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Tacrolimus clearance varies significantly after lung transplant. A population pharmacokinetic model incorporating patient factors can help personalize tacrolimus dosing for better outcomes.

Keywords:
critical illnesslung transplantationpharmacogeneticspharmacokineticsprecision dosingtacrolimus

More Related Videos

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

7.6K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.1K

Related Experiment Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.8K
Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

7.6K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
00:05

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.1K

Area of Science:

  • Pharmacokinetics
  • Immunosuppression
  • Transplant Medicine

Background:

  • Tacrolimus is a key immunosuppressant post-lung transplant.
  • Early tacrolimus exposure variability is linked to adverse outcomes.
  • Limited data exist on early post-lung transplant tacrolimus pharmacokinetics.

Purpose of the Study:

  • To develop a population pharmacokinetic model for tacrolimus in early post-lung transplant recipients.
  • To identify key covariates influencing tacrolimus clearance in this population.

Main Methods:

  • Retrospective pharmacokinetic study of 270 lung transplant recipients.
  • Nonlinear mixed-effects modeling to create a population PK model.
  • Validation in a separate cohort of 114 patients; covariate analysis performed.

Main Results:

  • A 1-compartment model with fixed absorption rate was developed.
  • Postoperative day, hematocrit, transplant type, CYP3A5 genotype, weight, and CYP inhibitor drug exposure influenced tacrolimus clearance.
  • Tacrolimus clearance increased over 3-fold by postoperative day 14.

Conclusions:

  • Tacrolimus clearance is highly dynamic in the early post-lung transplant phase.
  • Population PK models with transplant-specific covariates can inform precision dosing.
  • Further multicenter studies are needed to refine these models.